MAIA Biotechnology(MAIA)

CHICAGO, ILBiotechnology1 H-1B visas (FY2023)

Focus: MAIA Biotechnology is a public-stage biotech company focused on peptide-based cancer therapies, headquartered in Chicago. The company maintains a diversified portfolio spanning oncology pipeline programs and legacy generic/specialty medications.

Oncology

Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About MAIA Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow MAIA Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Key Products

SODIUM PHENYLACETATE AND SODIUM BENZOATE

Hepatic Encephalopathy

Peak

Only NDA-derived marketed product; flagship branded therapy with no imminent LOE.

Help build intelligence for MAIA Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline focus on novel peptide cancer therapies (6-Thio-2'-Deoxyguanosine in Phase 2/3 NSCLC) offers exposure to cutting-edge oncology science
Public company status provides liquidity, equity transparency, and established infrastructure absent in early-stage biotech
Diversified product portfolio including marketed generics and specialty products provides operational stability

Watch Out For

Zero current job openings (activeJobCount = 0) signals hiring freeze or organizational contraction despite public status
Significant operating losses ($23.3M net loss in FY2025, $19.8M in FY2024) with minimal R&D spend ($454K in FY2025, down 96% YoY) suggests financial distress or strategic pivot
Sparse pipeline (only 3 programs total, all early-stage) and minimal clinical trial activity (1 Phase 1, 1 Phase 2, 1 Phase 3) indicate limited near-term catalysts
No published scientific output (0 publications on record) raises questions about internal research capability and academic credibility

Generated by Claude from MAIA Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.